Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares saw an uptick in trading volume on Wednesday . 722,532 shares were traded during trading, an increase of 270% from the previous session’s volume of 195,511 shares.The stock last traded at $4.08 and had previously closed at $3.85.

A number of brokerages have recently issued reports on DRNA. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Sunday, June 26th. Chardan Capital dropped their price target on shares of Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating on the stock in a research report on Monday, August 8th. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 25th. Stifel Nicolaus dropped their price target on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, June 30th. Finally, Leerink Swann reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Thursday, June 30th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $11.85.

The stock’s 50-day moving average price is $3.38 and its 200-day moving average price is $3.94. The company’s market cap is $84.67 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. Analysts expect that Dicerna Pharmaceuticals Inc. will post ($3.17) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Paloma Partners Management Co acquired a new position in shares of Dicerna Pharmaceuticals during the second quarter worth approximately $183,000. A.R.T. Advisors LLC acquired a new position in shares of Dicerna Pharmaceuticals during the second quarter worth approximately $170,000. FMR LLC boosted its position in shares of Dicerna Pharmaceuticals by 0.4% in the second quarter. FMR LLC now owns 3,108,916 shares of the biopharmaceutical company’s stock worth $9,327,000 after buying an additional 11,719 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Dicerna Pharmaceuticals by 44.9% in the second quarter. Dimensional Fund Advisors LP now owns 34,273 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 10,616 shares during the last quarter. Finally, Oxford Asset Management boosted its position in shares of Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 149,560 shares during the last quarter. Institutional investors and hedge funds own 62.38% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.